Protagonist Therapeutics inc

Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of innovative peptide-based drugs to address unmet medical needs. The company was founded in 2001 and is headquartered in Newark, California, United States.

Protagonist Therapeutics is dedicated to leveraging the power of peptides, which are short chains of amino acids that play crucial roles in various biological processes, to develop therapeutic solutions for diseases that currently have limited treatment options. By targeting specific disease targets using peptide-based drugs, the company aims to provide patients with safer and more effective treatment options compared to traditional small molecules or biologics.

Peptides have numerous advantages as therapeutic agents, including high specificity, low immunogenicity, and excellent safety profiles. Protagonist Therapeutics utilizes its proprietary technology platform, called Peptidomics, to design and optimize peptide-based therapeutics with desired properties such as stability, selectivity, and oral bioavailability.

The company*s pipeline includes a diverse range of programs in different stages of development, targeting various disease indications. Protagonist Therapeutics* lead product candidate is PTG-300, which is being developed for the treatment of iron overload disorders such as hereditary hemochromatosis and beta-thalassemia. PTG-300 is a hepcidin mimetic peptide designed to regulate iron homeostasis by inhibiting iron absorption and mobilizing excess iron from tissues.

Another important program in the company*s pipeline is PTG-200, being developed for the treatment of inflammatory bowel disease (IBD), which includes conditions like Crohn*s disease and ulcerative colitis. PTG-200 is an oral interleukin-23 receptor antagonist designed to modulate the activity of the immune system and reduce the inflammation associated with IBD.

Protagonist Therapeutics has also partnered with major pharmaceutical companies like Janssen Biotech, a subsidiary of Johnson & Johnson, to develop and commercialize certain peptide-based drug candidates. These collaborations help the company in bringing its innovative therapies to market while leveraging the resources and expertise of its partners.

In addition to its research and development efforts, Protagonist Therapeutics also focuses on advancing its manufacturing capabilities to support the eventual commercialization of its pipeline products. The company strives to ensure the scalability and consistency of its manufacturing processes to meet the demand once regulatory approvals are obtained.

Overall, Protagonist Therapeutics Inc. is a biopharmaceutical company that harnesses the therapeutic potential of peptides to develop innovative drugs for various disease indications. With its dedication to scientific innovation, a strong pipeline of product candidates, and strategic partnerships, the company aims to make a significant impact on patients* lives and the field of medicine.